Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
14
0
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+9 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (14)
Showing 10 of 14 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Project Leader
Ono Pharmaceutical Co., Ltd.
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (14)
Showing 14 of 14 trials
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
All 14 trials loaded